Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12605568 | 0.85 | KMT2A (0.56) | KMT2AKDM4ECXCR3MAPK1CYP3A4 | |
| SCHEMBL3589774 | 0.80 | GRIN2B (0.53) | CYP2C19KCNH2 | |
| SCHEMBL12605547 | 0.80 | GRIN2B (0.57) | KMT2AKDM4EMAPK1CYP3A4CYP2C19 | |
| SCHEMBL16897931 | 0.79 | KMT2A (0.52) | KMT2AKDM4ECXCR3RAD52MAPK1 | |
| SCHEMBL16897910 | 0.76 | NOTUM (0.48) | KMT2AKDM4ERAD52CYP3A4KCNH2 | |
| SCHEMBL24814484 | 0.74 | KMT2A (0.65) | KMT2AKDM4ENTSR1RAD52MAPK1 | |
| SCHEMBL31672359 | 0.72 | KRAS (0.46) | KMT2AKDM4ECXCR3HRH3OPRD1 | |
| SCHEMBL16117855 | 0.72 | KRAS (0.46) | KMT2AKDM4ECXCR3HRH3OPRD1 | |
| SCHEMBL9701534 | 0.72 | KMT2A (0.71) | KMT2ANTSR1MAPK1CYP3A4CYP2C19 | |
| SCHEMBL30074152 | 0.72 | KMT2A (0.71) | KMT2ANTSR1MAPK1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091984-B1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3091984-B1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10611741-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2020-04-07 | — | — | US | disclosed |
| US-10611741-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | NANOSYN INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | NANOSYN INC. | 2019-04-11 | — | — | US | disclosed |
| US-10087151-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTIMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3091984-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2015106025-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015106025-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326123-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | CYP4B1, XDH, UGT2B7 | KMT2A 2235/4885KDM4E 2233/4885NTSR1 3505/4885 |
| US-10611741-B2 | Substituted benzoxazine and related compounds | ABCG2, XDH, CYP3A5 | KMT2A 2162/4885KDM4E 1738/4885NTSR1 4352/4885 |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | CYP4B1, XDH, UGT2B7 | KMT2A 2235/4885KDM4E 2233/4885NTSR1 3505/4885 |
| US-10087151-B2 | Substituted benzoxazine and related compounds | CYP4B1, XDH, UGT2B7 | KMT2A 2235/4885KDM4E 2233/4885NTSR1 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.